Dr. Kang got comprehensive pharmaceutical training in the pharmaceutical universities in China. He received his Ph.D. degree in the Chinese University of Hong Kong. Now he is a post-doctoral research fellow in the Department of Translational Hematology and Oncology Research, Lerner Research Institute, Cleveland Clinic. He has long experience in translational study in tumor field. His current main interest is to study the immune priming effects of low dose hypomethylation agents against cancer in vitro and in vivo.

Drug research and development; Translational study against human disease; Tumor immunotherapy